Skip to main content

Super navigation

  • Now approved in the US: VYVGART
  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases

Press Releases

  • Any
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • (-) 2011
  • 2010
  • 2009
Reset

2011

November 30, 2011
arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round
November 29, 2011
arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets
September 6, 2011
arGEN-X presents significant progress at Biopharm America 2011
July 25, 2011
arGEN-X announces non-exclusive license with BioWa for Potelligent® technology
May 15, 2011
arGEN-X initiates a second pre-clinical development program in under 18 months from start of operations
January 4, 2011
arGEN-X signs discovery and development alliance with Lilly
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2022 © argenx
Disclaimer
Privacy policy
Regulations